Charlie Craddock CBE

Bone marrow transplant doc

[Charlie Craddock CBE @charliecraddock]

Outstanding presentation by @vicpotter123 on UK transplant trial portfolio delivered through IMPACT network. Only possible because of generous funding from @CureLeukaemia @AnthonyNolan and @NHSBT and coordinated by @act4patients

[Charlie Craddock CBE @charliecraddock]

Great talks by Mike Dennis and Steve Knapper on the UK AML Research Network clinical trial portfolio. Important practice informing studies in newly diagnosed fit and unfit patients. Underpinned by funding from @CureLeukaemia @bloodcancer_uk

[Charlie Craddock CBE @charliecraddock]

Great talk about the new UK AML Research Network website pioneered by Anjum Khan and Tom Coates. Generously supported by @act4patients and funded by @CureLeukaemia

[Charlie Craddock CBE @charliecraddock]

Was a great privilege to discuss in such a relaxed format varied strategies to improve transplant outcome in AML and the vital need for prospective trials. Fantastic initiative from @NicoGagelmann and Nick Kroger!

[MYTHS & FACTS on Hematology and Cell Therapy @MythsFactsPod]

Conditioning intensity MATTERS for allogeneic transplant.

Charles Craddock joins us to discuss the major aims of conditioning regimens prior to allogeneic stem cell transplantation.

Full episode September 6.

Watch on YouTube:
https://t.co/3IoeBGje2E

@charliecraddock

[Charlie Craddock CBE @charliecraddock]

Privileged to work with such gifted and creative colleagues in order to deliver innovative drug and transplant trials for AML patients. International collaboration driving powerful synergies. @act4patients @CureLeukaemia

[Naveen Pemmaraju, MD @doctorpemm]

👉👉👉Wonderful to keep our robust international 🌍#BPDCN & #leusm collaboration going with Prof .@charliecraddock Prof .@Daver_Leukemia Prof Pemmaraju all together @_MDEducation !! 🙌

[Charlie Craddock CBE @charliecraddock]

Tour de 4 is more than just a ride; it’s a movement that brings hope to those facing Stage 4 cancer. Every donation helps fund vital support for patients and their families. Please consider contributing or sharing this cause to make a difference. https://t.co/XRSzlM5uOV

[Charlie Craddock CBE @charliecraddock]

Driven by a relentless patient focus Geoff has transformed UK blood cancer research. The inspiration behind both the TAP and IMPACT networks which have recruited >3,000 patients to pivotal trials and @act4patients Geoff has provided a roadmap for the future. Amazing achievement!

[Chris Fox @ProfChrisPFox]

And what a fantastic patron, champion and role-model the ever-modest Geoff has been! 👏🏾 👏🏾

[Chris Fox @ProfChrisPFox]

“Let’s talk Blood Cancer”
A fantastic podcast venture from @CureLeukaemia : patient-focused & accessible info.
Hopefully digestible & myth-busting!
Kudos #AdamJoyce 👏🏾 the host with the most!
@act4patients @charliecraddock @NottmBRC @NottmCRF @drpramilak @PaulSherringto7

[Charlie Craddock CBE @charliecraddock]

Outstanding AML presentations at @BritSocHaem from @Priyankamehta71 @drpramilak Mike Dennis and Steve Knapper. Flagging new UK trials in fit and unfit adults and vital importance of MyeCare Registry and INTERCEPT-UK Relapse platform

[Charlie Craddock CBE @charliecraddock]

Agreed Chris. An uplifting 36 hours with focus on clinical algorithms, trials and trainees and mentorship- all with the aim of improving patient outcomes at a time of enormous therapeutic promise. Brilliant organisation skills from Hartley Taylor who worked their magic again!

[Chris Fox @ProfChrisPFox]

What a fabulous inaugural SOHO UK meeting in London. World class speakers across the blood cancer field integrated with fantastic speakers on leadership, a mentorship programme, industry and charity partners & much more… hats off to @charliecraddock @HT_Medical @SocietyofHemOnc

[ESH (Haematology) @ESHaematology]

🚀 Session V on HSC Transplantation at #ESHAL2026 continues with Dr. @charliecraddock (Birmingham), delivering an outstanding talk on a critical issue: “Post-transplant therapies in AML - for which, for whom and how?”

Chairs: Victoria Potter and @JurjenVersluis

[Charlie Craddock CBE @charliecraddock]

Outstanding work Sridhar! Great concept- impressive trial delivery!

[Sridhar Chaganti @SridharChaganti]

Delighted to share initial results of the CRUK ph I/II trial of aleta 001, a 1st in class CAR T engager protein at #ASH2025
✅ Excellent safety profile
✅ No DLTs
✅ No SAEs beyond gr1 CRS
✅ Robust and sustained CAR T expansions @BioAleta @PDRennert @immunologydoc @uhbtrust

[Nico Gagelmann @NicoGagelmann]

This year's #ASH25 presents exciting number of prospective trials in allogeneic transplantation

Here's a list of potential high impact abstracts @ASH_hematology

[Charlie Craddock CBE @charliecraddock]

Exciting prospects for improving the drug and transplant management of AML! Tremendous series of abstracts at this year’s ASH.

[AML Hub @AML_Hub]

In case you missed it, you can find the ASH 2025 top abstracts here: https://t.co/ehhD6JD9eg

[AK Eisfeld @AkEisfeld]

Thank you @charliecraddock @Daver_Leukemia for such an amazing meeting—inspired by the talks and excited to see what we can all do together! @OSUCCC_James @act4patients

[MD Education @_MDEducation]

Two sides. One question. Today’s debate at the AML–ALL EU Focus Meeting 2025: Allo-mandatory adults with MRD+ CR1 AML — Should they proceed directly to transplant? 🎤

For: @charliecraddock | Felicitas Thol, MD
Against: Stéphane de Botton, MD | @drpramilak

Watch the full debate and expert perspectives: https://t.co/XkqSka0cZo

#MDEducation #AML #Hematology #Transplant

[Charlie Craddock CBE @charliecraddock]

Important data from @AkEisfeld highlighting critical importance of genomic characterisation of different racial groups. Vital to optimise patient outcomes and deliver equity. Underpinning principle of @act4patients MyeCare AML Registry. @CureLeukaemia @AnthonyNolan @LeukUK

[Charlie Craddock CBE @charliecraddock]

Outstanding presentations and great discussion at this excellent meeting.

[MD Education @_MDEducation]

Day 1 of the 4th Annual AML-ALL EU Focus Meeting 2025 is officially underway in Athens 🇬🇷

Join the waitlist for meeting recordings here: https://t.co/XkqSka0cZo

Co-chaired by Drs. @Daver_Leukemia, @cpapayannidis, Elias Jabbour, MD, and @charliecraddock, today’s agenda explores the latest advances in AML and ALL, spanning:
▪️ Evolving treatment paradigms in AML
▪️ Risk stratification and MRD in ALL
▪️ Integration of novel targeted and cellular therapies

#MDEducation #Hematology #AML #ALL

[Daniel Peters @DPetersMD]

7/
ImmunoTx in AML
@charliecraddock : “GVL remains our most potent anti-leukemia therapy.”
It’s CD8+ T-cell driven.

🙋🏽‍♂️So why doesn’t CAR-T work?
M. Levis: “CRS is like bathing AML in myeloid growth factors.”
Many other reasons too—so it’s still a puzzle. #CellTherapy

[Joshua Zeidner MD @LeukDocJZ]

So great to catch up with the best colleagues at #ESHAML2025 in Estoril 🇵🇹 @charliecraddock @jaltmanmd @DrChrisHourigan